Clinical Utility of TSH Receptor Antibodies
- 1 June 2013
- journal article
- review article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (6), 2247-2255
- https://doi.org/10.1210/jc.2012-4309
Abstract
TSH receptor antibodies (TRAb) cause Graves' disease (GD) hyperthyroidism. Widely available TRAb measurement methods have been significantly improved recently. However, the role of TRAb measurement in the differential diagnosis of hyperthyroidism, the prediction of remission of GD hyperthyroidism, the prediction of fetal/neonatal thyrotoxicosis, and the clinical assessment of Graves' ophthalmopathy (GO) are controversial. We reviewed and analyzed the literature reporting primary data on the clinical use of TRAb. We focused our analyses on clinical studies analyzing third-generation TRAb assays. The performance of TRAb in the differential diagnosis of overt hyperthyroidism is excellent, with sensitivity and specificity in the upper 90%. TRAb can accurately predict short-term relapses of hyperthyroidism after a course of antithyroid drugs but are less effective in predicting long-term relapses or remissions. Pregnancies in women with GD with negative TRAb are highly unlikely to result in fetal hyperthyroidism, whereas high titers of TRAb in pregnancy require careful fetal monitoring. GD patients with GO frequently have high TRAb levels. However, there are insufficient data to use the test to predict the clinical course of GO and response to treatment. Third-generation TRAb assays are suitable in the differential diagnosis of hyperthyroidism. In GD, TRAb should be tested before deciding whether methimazole can be stopped. TRAb should be used in pregnant women with GD to assess the risk of fetal thyrotoxicosis. The use of TRAb in GO requires further studies.Keywords
This publication has 84 references indexed in Scilit:
- Immunopathogenesis of Graves’ ophthalmopathy: The role of the TSH receptorBest Practice & Research Clinical Endocrinology & Metabolism, 2012
- Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and PostpartumThyroid®, 2011
- Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical EndocrinologistsThyroid®, 2011
- Neutral Antibodies to the TSH Receptor Are Present in Graves’ Disease and Regulate Selective Signaling CascadesEndocrinology, 2010
- Measurement of Thyroid Blood Flow Area Is Useful for Diagnosing the Cause of ThyrotoxicosisThyroid®, 2005
- A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' diseaseClinical Endocrinology, 1998
- Color Flow Doppler Sonography Rapidly Differentiates Type I and Type II Amiodarone-Induced ThyrotoxicosisThyroid®, 1997
- Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clonesBiochemical and Biophysical Research Communications, 1990
- Universal Predictive Criteria for Neonatal Overt Thyrotoxicosis Requiring TreatmentAmerican Journal of Perinatology, 1988
- VALUE OF THYROID-STIMULATING-ANTIBODY DETERMINATIONS IN PREDICTING SHORT-TERM THYROTOXIC RELAPSE IN GRAVES' DISEASEThe Lancet, 1977